Search

Search for a specific protein in the Platelet Interactome


(Example: vasp)

 

Advanced Search

Get detailed protein information focusing on various characteristics and extract interaction networks

 

Legend

 

About

Go Back

Description for Protein ESR1

estrogen receptor 1
266 total interacting proteins; 108 platelet interacting proteins
Icon Book Platelet Evidence (proteome studies/others : 0/0)
(Not detected in platelets)
Summary:
This gene encodes an estrogen receptor, a ligand-activated transcription factor composed of several domains important for hormone binding, DNA binding, and activation of transcription. The protein localizes to the nucleus where it may form a homodimer or a heterodimer with estrogen receptor 2. Estrogen and its receptors are essential for sexual development and reproductive function, but also play a role in other tissues such as bone. Estrogen receptors are also involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. Alternative splicing results in several transcript variants, which differ in their 5' UTRs and use different promoters. [provided by RefSeq] (PubMed Links)
Domains and Motifs:
  • ZnF_C4: c4 zinc finger in nuclear hormone receptors
  • HOLI: Ligand binding domain of hormone receptors
    • Gene Ontology:
    Gene Ontology Annotations
    KEGG - Enzyme ID(s):
    None Available
    KEGG - Orthology:
    K08550
    KEGG - Pathway(s):
    None Available
    Nomenclature / Alternative Names:
    Estrogen receptor 1; Estrogen receptor; ESR; ER; ESRA; Oestrogen receptor alpha; NR3A1; DKFZp686N23123; dJ443C4.1.1; Era
    Approved Symbol:
    ESR1
    (De-) Phosphorylations:
    Total (de-) phosphorylation sites: 23
    Human (de-) phosphorylation sites: 23; No platelet phosphorylation sites
    Phosphorylation Targets:
    Total phosphorylation targets: 0
    Human phosphorylation targets: 0;Predicted platelet targets: 0
    		Protein Characteristics:
    Isoform-specific Information
    Icon DrugsAssociated Drugs (DrugBank Accession):

  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL(db);
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL(db);
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL(db);
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL(db);
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL(db);
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL(db);
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL(db);
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol(db);
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN(db);
  • 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE(db);
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol(db);
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL(db);
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL(db);
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol(db);
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL(db);
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL(db);
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL(db);
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL(db);
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL(db);
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol(db);
  • Allylestrenol(db);
  • Chlorotrianisene(db);
  • Clomifene(db);
  • Compound 15(db);
  • Compound 16(db);
  • Compound 18(db);
  • Compound 19(db);
  • Compound 4-D(db);
  • Conjugated Estrogens(db);
  • Danazol(db);
  • Desogestrel(db);
  • Dienestrol(db);
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE(db);
  • Diethylstilbestrol(db);
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate(db);
  • Estradiol(db);
  • Estramustine(db);
  • Estriol(db);
  • Estrone(db);
  • Estropipate(db);
  • Ethinyl Estradiol(db);
  • Ethynodiol Diacetate(db);
  • Etonogestrel(db);
  • Fluoxymesterone(db);
  • Fulvestrant(db);
  • Genistein(db);
  • Levonorgestrel(db);
  • Medroxyprogesterone(db);
  • Melatonin(db);
  • Mestranol(db);
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE(db);
  • Naloxone(db);
  • Norelgestromin(db);
  • Norgestimate(db);
  • Norgestrel(db);
  • Progesterone(db);
  • Quinestrol(db);
  • Raloxifene(db);
  • RALOXIFENE CORE(db);
  • Tamoxifen(db);
  • Toremifene(db);
  • Trilostane(db);
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE(db)

    Associated Genetic Diseases:

  • Estrogen receptor mutant, temperature-sensitive(Pd);
  • Estrogen resistance(Pd);
  • HDL cholesterol, augmented response of, to hormone replacement(Pd);
  • Migraine, susceptibility to(Pd)
    		• Predicted Transmembrane Domains:
  • Isoform 4 : 0
  • Isoform 3 : 0
  • Isoform 2 : 0
  • Isoform 1 : 0
    • Additional Identifiers:

    HPRD: 00589 Entrez Gene ID: 2099 OMIM ID: 133430 Swissprot Accession: P03372; Q5T5H7; Q9UBT1;